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Purpose: A fragment of type II procollagen, chondrostatin, contains the
classic integrin binding sequence RGDRGD. This sequence is conserved
across species, indicating potential biological function. We have previ-
ously shown that the integrin avb3 and avb5 mediate cell adhesion to
chondrostatin. A substantial and persuasive body of data supports the
view that integrins plays a critical role in the pathogenesis of arthritic
diseases by participating in cell migration, apoptosis and other cellular
processes. The goal of this study was to determine effects of chondro-
statin on angiogenesis.
Methods: Site-directed mutagenesis was used to mutate the RGD to
RAD in chondrostatin. The tube formation assay was performed by seed-
ing HUVEC into a Matrigel-coated plate in the presence of recombinant
proteins. The formation of tubes was visualized by light microscopy and
quantiﬁed by a Q Capture Pro imaging software. The aortic ring formation
assay was performed by culturing aorta rings of 5 to 10-week Fischer
rat in 3D collagen gels at 37ºC for a week in the presence of FGF
and recombinant proteins. The image was captured with an Olympus
microscope and total length of the microvessel outgrowth was quantiﬁed.
Mouse corneal assay was performed by implanting polyHEMA pellets
containing FGF into the mouse corneas of 6-week-old Balb/c mice. The
mice received osmotic pumps containing recombinant proteins for one
week. The mice were sacriﬁced and the total length of ﬂuorescently
labeled vessels was quantiﬁed.
Results: Three different assays were performed to determine the ability
of chondrostatin to inhibit angiogenesis. In the tube formation assay, re-
combinant chondrostatin (Fig 1B), but not mutated chondrostatin (data not
shown) or GST alone (Fig 1A), inhibited HUVEC cell tube formation in a
dose-dependent manner (Fig 1C). In the aortic ring assay, chondrostatin,
but not mutated chondrostatin or GST alone, inhibited FGF-stimulated
microvessel outgrowth (Fig 2A). The inhibition is also dependent on the
concentration of chondrostatin (Fig 2B). In the in vivo mouse corneal
assay, chondrostatin inhibited vascularization as seen in the ﬂuorescence-
labeled mouse cornea (Fig 3A). The inhibition is dose-dependent, as 5 mM
of chondrostatin only inhibited the vessel formation by 40% while 25 mM of
chondrostatin suppressed vessel formation by 65% of the control (Fig 3B).
Fig. 1. Chondrostatin inhibits HUVEC tube formation: in vitro tube forma-
tion assay.
Conclusions: We previously showed that integrins avb3 and avb5 me-
diated chondrostatin-cell interaction. As endothelial cells express these
integrins, this study was designed to investigate the effect of chondrostatin
on angiogenesis. The results from three different angiogenesis assay
methods showed that chondrostatin is an effective angiogenesis inhibitor
and the inhibition is RGD-dependent. The ability of the chondrostatin
to inhibit angiogenesis makes it a potential antitumor agent, since mi-
crovascular endothelial cells, which are recruited by tumors, have become
an important target in tumor therapy. In addition, chondrostatin is a
naturally occurring peptide liberated from the collagen molecule during
Fig. 2. Chondrostatin inhibits rat aortic ring outgrowth: rat aortic ring
assay.
Fig. 3. Chondrostatin inhibits mouse corneal vascularzation: mouse
corneal assay.
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biosynthesis and contains vicinal RGD motif that bind speciﬁcally to aVb3
and aVb5 integrins. Since chondrostatin reaches the highest level during
cartilage formation and it inhibits angiogenesis, it is an excellent candidate
for the molecular mechanism by which cartilage remains avascular.
A10 TRANSFORMING GROWTH FACTOR-BETA INDUCES
PERSISTENT SYNOVIAL FIBROSIS WHILE CONNECTIVE
TISSUE GROWTH FACTOR-INDUCED FIBROSIS IS
REVERSIBLE. ROLE FOR LYSYS HYDROXYLASE
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Purpose: The main characteristics of osteoarthritis are cartilage dam-
age, osteophyte formation and synovial ﬁbrosis. Synovial ﬁbrosis can
contribute to the loss of the function of an OA joint. TGF-b is considered
one of the main players in ﬁbrotic diseases. However, CTGF, which can be
induced by TGF-b, has been reported to be an important player as well,
stated to contribute to maintenance of ﬁbrotic tissue. We investigated the
underlying mechanism in that leads to the observed difference in ﬁbrosis
persistence between TGF-b- and CTGF.
Methods: We injected C57Bl/6 mice intra-articularly with Ad-TGF-b or
Ad-CTGF. After 3, 7 and 21 days knee joint synovial tissue was isolated
for RNA isolation or whole knee joints for histology. With Q-RT-PCR
relative mRNA levels were determined of matrix molecules, proteases,
protease inhibitors, and growth factors. To analyze the enzymes involved
in collagen cross link formation, mRNA expression of lysyl hydroxylase
(LH) was determined.
CTGF-levels induced by TGF-b were measured by ELISA in 24 hour
patella-synovial wash-outs of C57Bl/6 mice intra-articularly injected with
Ad-TGF-b (3, 7 and 14 days).
Results: TGF-b and CTGF induced synovial ﬁbrosis in murine knee joints
as shown by histology (as observed by an increase in synovial width).
However, TGF-b-induced ﬁbrosis was very persistent, whereas CTGF-
induced ﬁbrosis resorbed by day 28.
TGF-b induced elevated collagen type I and very high levels of aggrecan
expression and hardly any changes in collagen type II and III. CTGF
induced no clear changes in collagen type I, II and III. CTGF even
decreased aggrecan expression (day 21 only).
CTGF induced no changes in MMP3, -9, -13, ADAMTS-4 or -5, whereas
TGF-b increased MMP-3, -13 and ADAMTS4. Thus elevated levels of
matrix degrading enzyme expression cannot explain the less persistent
CTGF-induced ﬁbrosis.
TIMP1 (associated with matrix accumulation in ﬁbrotic disorders), was
highly up regulated by TGF-b (all days) and only slightly up regulated by
CTGF (day 7). TGF-b also induced elevated mRNA levels of TGF-b1 and
CTGF.
Only TGF-b induced high levels of LH expression, especially LH2b, which
has been implicated in hard-to-degrade collagen linkage and was found
up regulated in ﬁbrotic lesions.
As TGF-b can induce CTGF and up regulated CTGF mRNA in our
experiments, we measured CTGF levels in 24 hour patella-synovial wash
outs and found that TGF-b induced 64 ng CTGF/ml after 3 days and that
CTGF levels were still elevated by day 14.
Conclusions: TGF-b induced increased collagen type I and aggrecan
mRNA levels in synovial tissue, but also high levels of degrading enzymes.
The latter does not explain the persistent nature of TGF-b versus CTGF-
induced synovial ﬁbrosis. Lack of collagen type I mRNA induced by
CTGF corresponds to ﬁndings of other groups. Despite this fact, ﬁbrosis
is found. Only TGF-b induced high levels of TIMP1 expression, which
was previously found associated with strain dependent ﬁbrosis sensitivity
in mice and implicated in accumulation of ECM in ﬁbrotic disorders.
TGF-b, not CTGF, induced high levels of LH which are crucial for ECM
cross linking. Moreover, LH2b was reported by van der Slot et al. to
induce harder-to-degrade crosslinks compared to LH2a. The 2b splicing
variant was highly expressed upon stimulation with TGF-b. Since TGF-b
clearly up regulated MMP expression a dominant role for TIMP appears
unlikely. The strong induction of LH2b by TGF-b compared to CTGF, and
consequently harder to degrade cross links, appears to be the most likely
cause of the induction of irreversible ﬁbrosis by TGF-b.
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Purpose: There is increasing evidence for intra-articular hyaluronic acid
and especially corticosteroids in the treatment of osteoarthritis (OA) from
studies using ﬂuroscopy guidance or triple ultrasound guided injections.
Having previously demonstrated the accuracy of ultrasound guided in-
jection and how competency can be achieved we aimed to demonstrate
the duration of objective improvement in pain, function and global health
assessment in patients with moderate/severe hip OA with a single intra-
articular injection.
Methods: 77 patients with hip OA were recruited to a prospective, ran-
domised controlled trial and randomised to one of four groups: standard
care (non-injection group), normal saline (3mls), non-animal stabilized
hyaluronic acid (durolane, 3mls/60mg) and methylprednisolone acetate
(depomedrone, 3mls/120mg). All patients met the ACR criteria for hip
OA. Those in the injection groups received a single ultrasound guided
injection. All baseline data were obtained with both patients and inves-
tigators blinded to the group allocation, and injection patients remained
blinded throughout the study. The primary outcome measure was ‘worst
pain’ using a numerical rating scale (NRS 0−10), and other outcome mea-
sures included the aggregate pain and function scales of the WOMAC.
These evaluations were performed at baseline and weeks 1, 4, 8 and 16.
Results: Mean age was 69 (SD 8) years. Mean BMI was 28.5 (SD 5.2)
kg×m−2. The 4 groups were matched with respect to age, BMI, and
scores of the outcome measures (ANOVA). At week 1 and week 4 there
was a signiﬁcant improvement in NRS pain, as well as WOMAC pain
and function for the steroid arm with the differences being statistically
signiﬁcant compared to all the other groups; the effect sizes were striking:
1.5 for NRS pain, 1.9 for WOMAC pain and 1.3 for WOMAC function
at week 1. There were 22 responders as deﬁned by the OMERACT-
OARSI responder criteria in an intention to treat analysis at week 1:
14 in the steroid group (74%), 4 in saline group (21%), 2 in durolane
group (11%) and 2 in non-injection group (10%); Chi-squared test for
comparison between the groups, p< 0.001. At 8 weeks the differences
were still signiﬁcant between the steroid group and the saline group (NRS
pain: t test, p 0.018).
Conclusions: This is the ﬁrst single ultrasound guided injection study in
hip OA comparing a moderately high dose of corticosteroid, hyaluronic
acid, a control injection and standard care. Our data demonstrate the
efﬁcacy of intra-articular corticosteroid, with a statistically signiﬁcant and
clinically important improvement in pain and function sustained for at
least 8 weeks post injection, suggesting this is an important and practical
treatment option for those with moderate/severe hip OA.
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Purpose: Purpose: Our previous studies had shown that bilateral total
meniscectomy (BTM) in merino sheep resulted in pathological changes in
articular cartilage (AC), subchondral bone and synovial tissues that were
progressive and simulated the development of early human osteoarthritis
(OA). We previously used this animal model to evaluate potential disease-
modifying OA drugs. Mesenchymal stem cells (MSC) + bio-scaffolds
have been widely investigated for their ability to enhance repair of
chondral/osteochondral defects, but their chondroprotective effects when
injected directly into OA joints has received limited attention. The objective
of this study was to address this deﬁciency using immunoselected Stro-3+
mesenchymal precursor stem cells (MPC) in the BTM model.
Methods: BTM was undertaken in 36 adult Merino wethers. Two weeks
post BTM, joints were randomly injected with either 2mL high MW
Hyaluronan (HA) or 2mL allogenic Stro-3+ MPC suspended in HA. Four
doses of MPC were studied: Group A = 10 million (mil) MPC [n = 6];
Group B = 25 mil MPC [n = 6]; Group C = 100 mil MPC [n = 18] and
Group D = 150 mil MPC [n = 6]. Groups A, B and D were sacriﬁced
